• The Journal of Korean Physical Therapy
• /
• v.23 no.3
• /
• pp.37-42
• /
• 2011

Purpose: The principal objective of this study was to evaluate the power output of ultrasound in Korean clinics and compare the value with Korean and global standards. Methods: A total of 69 units were measured for ultrasound power output. The normal range of power output level was ${\pm}30%$ of the output set according to KFDA standards. Device model, manufacturer, ERA, and BNR were obtained via simple questionnaires. A portable ultrasound power meter was used for output measurement. Results: 37 machines, with reported ERA values, were assessed for power output per unit area. Of these machines, 13 (37.14%) were considered to be compliant with US FDA standards at 0.5, 1.0, 1.5, $20W/cm^2$ and 18 (51.43%) were considered within KFDA standards. The remainder of the machines were outside the standard error and evidenced irregular output levels, even though most of them were the same model. Conclusion: Appropriate ultrasound intensity is incredibly important for safety and effective use. Therefore, the KFDA standards regarding ultrasound may require revision in light of global standards, including BNR and ERA additionally, attention should be paid to regular calibration for safe use in clinical practice.

• Journal of Environmental Health Sciences
• /
• v.36 no.5
• /
• pp.435-439
• /
• 2010

In Korea, food-risk shock announcements are made one or more times annually; such as last September, 2010 when Seoul City revealed a very high concentration of cadmium in small octopus intestines sold in Korea. As a result, consumers avoided eating domestic as well as imported small octopus. Fishermen protested against Seoul city; however, the Korean Food and Drug Administration (KFDA) announced that small octopus intestines pose no safety risk. The conflict between KFDA and Seoul City on the safety of small octopus intestines amplified the confusion of consumers. The small octopus cadmium shock resembled previous food-risk shocks in many respects. Effective risk communication is important in resolving food risk shocks as risk affects people case-by-case; for example people who do not eat small octopus intestines should not be at any risk, but those who do enjoy small octopus intestines, especially one more times per week, could be at risk. Therefore, it is necessary to communicate different risk messages to people or groups with different eating habits. From this point of view, the risk message conveyed by the KFDA on small octopus intestines was not appropriate.

• Biomolecules & Therapeutics
• /
• v.11 no.1
• /
• pp.65-71
• /
• 2003

Terbinafine is a synthetic allylamine that is available in an oral formulation and is used at a dosage of 250mg/day. It is used as an active antifungal agent and inhibits the fungal enzyme squalene epoxidase, which leads to the accumulation of the sterol squalene, which is toxic to the organism. The purpose of the present study was to evaluate the bioequivalence of two terbinafine tablets, Lamisil (Novartis Korea Ltd.) and Terbinex (C-TRI Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). Eighteen normal male volunteers, 26.00$\pm$2.57 year in age and 70.51$\pm$9.36 kg in body weight, were divided into two groups and a randomized 2${\times}$2 cross-over study was employed. After one tablet containing 125 mg of terbinafine was orally administered, blood was taken at predetermined time intervals and the concentrations of terbinafine in plasma were determined using HPLC with UV detector. Pharmacokinetic parameters such as AUC, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC, $C_{max}$ and $T_{max}$ between two tablets were －4.191％, 5.223％ and －25.720％, respectively when calculated against the Lamisil, tablet. The powers (1-$\beta$) for AUC, $C_{max}$ and $T_{max}$ were 81％, 87％ and below 60％, respectively. Minimum detectable differences(.il) at alpha=O.1 and 1-/3=0.8 were less than 20％ (e.g., 19.72％ and 17.77％ for AUC and $C_{max}$, respectively). But minimum detectable differences($\Delta$) at alpha=0.1 and 1-$\beta$=0.8 for $T_{max}$ were more than 20％ (e.g., 26.25％). The 90％ confidence intervals were within $\pm$20％ (e.g., －17.440∼9.06 and －6.713∼17.160 for AUC and $C_{max}$ respectively). But 90％ confidence intervals for $T_{max}$ were not within $\pm$20％ (e.g., －43.346∼8.083). Another ANOVA test was conducted for logarithmically transformed AUC and $C_{max}$. These results showed that there are no significant differences in AUC and $C_{max}$ between the two formulations: The differences between the formulations in these log transformed parameters were all for less than 20％ (e.g., －4.19％ and 5.22％ for AUC and $C_{max}$, respectively). The 90％ confidence intervals for the log transformed data were not the acceptance range of log 0.8 to log 1.25 in AUC but the acceptance range of log 0.8 to log 1.25 in $C_{max}$ (e.g., log 1.13∼log 1.50 and log 0.94-log 1.22 for AUC and $C_{max}$ respectively). The major parameters, AUC and $C_{max}$ met the criteria of KFDA for bioequivalence although $T_{max}$ did not meet the criteria of KFDA (1998 year) for bioequivalence, indicating that Onfran tablet is bioequivalent to Zofran tablet. But in another ANOVA test AUC did not meet the criteria of KFDA (2002) for bioequivalence but $C_{max}$ met the criteria of KFDA (2002 year) for bioequivalence.or bioequivalence.equivalence.equivalence.equivalence.

• Journal of the Society of Cosmetic Scientists of Korea
• /
• v.42 no.1
• /
• pp.65-73
• /
• 2016

Korea Food and Drug Administration (KFDA) has officially announced 2,4-dinitrophenylhydrazine (DNPH) derivatization - high performance liquid chromatography (HPLC) methods for analysis of formaldehyde. This study was conducted to develop a convenient derivatization method for cosmetics by improving complex pre-treatment procedures included in KFDA method. To simplify pre-treatment procedures of KFDA method, reaction conditions including pH, time and temperature were optimized. This pre-treatment method does not require complicate pre-treatment steps of KFDA method such as pH adjustment of test solution with acetate buffer (pH 5.0), solvent-solvent partitioning with dichloromethane and concentrating procedure with vacuum evaporator. Formaldehyde-dinitrophenylhydrazone (formaldehyde-DNP) product produced by derivatization reaction was separated and quantified with a reversed-phase HPLC, which was slightly modified with KFDA method. The linearity test showed good results with 0.9999 of correlation coefficient ($r^2$) in the range of 2 ~ 40 ppm of standard solutions. In this method, limit of detection (LOD) and limit of quantitation (LOQ) values for formaldehyde were 0.2 ppm and 0.5 ppm, respectively. In addition, recovery test demonstrated that the method was also accurate and reproducible. Therefore, the proposed method can be applicable to rapid analysis of formaldehyde in cosmetics.

• Journal of Physiology & Pathology in Korean Medicine
• /
• v.24 no.1
• /
• pp.134-142
• /
• 2010

Although BinSo-San(BSS), a mixed herbal formula consisted of 11 types of medicinal herbs and have been used as anti-inflammatory agent, In the present study, the acute toxicity (single oral dose toxicity) of lyophilized BSS aqueous extracts was monitored in male and female mice after oral administration according to Korea Food and Drug Administration (KFDA) Guidelines (2005-60, 2005). In order to observe the 50% lethal dose ($LD_{50}$), approximate lethal dosage (ALD), maximum tolerance dosage (MTD) and target organs, test articles were once orally administered to female and male ICR mice at dose levels of 2000, 1000, 500, 250 and 0 (control) mg/kg (body wt.) according to the recommendation of KFDA Guidelines (2005-60, 2005). The mortality and changes on body weight, clinical signs and gross observation were monitored during 14 days after dosing according to KFDA Guidelines (2005-60, 2005) with organ weight and histopathology of 12 types of principle organs. We could not find any mortality, clinical signs and changes in the body weights except for dose-independent increases of body weight and gains restricted in 1000 mg/kg of BSS extracts-dosing female group. Hypertrophic changes of lymphoid organs.thymus, spleen and popliteal lymph nodes were detectedat postmortem observation with BSS extracts dose-dependent increases of lymphoid organ weights, and hyperplasia of lymphoid cells in these all three lymphoid organs at histopathological observations. These changes are considered as results of pharmacological effects of BSS extracts or their components, immunomodulating effects, not toxicological signs. In addition, some sporadic accidental findings such as congestion spots, cyst formation in kidney, atrophy of thymus and spleen with depletion of lymphoid cells, and edematous changes of uterus with desquamation of uterus mucosa as estrus cycles were detected throughout the whole experimental groups including both male and female vehicle controls. The significant (p<0.01) increases of absolute weights of kidney and pancreas detected in BSS extracts 1000 mg/kg-treated female group are considered as secondary changes from increases of body weights. The results obtained in this study suggest that the BSS extract is non-toxic in mice and is therefore likely to be safe for clinical use. The LD50 and ALD of BSS aqueous extracts in both female and male mice were considered as over 2000 mg/kg because no mortalities were detected upto 2000 mg/kg that was the highest dose recommended by KFDA and OECD. In addition, the MTD of BSS extracts was also considered as over 2000 mg/kg because no BSS extracts-treatment related toxicological signs were detected at histopathological observation except for BSS or their component-related pharmacological effects, the immunomodulating effects detected in the present study.

• 한국포장학회:학술대회논문집
• /
• 2007.04a
• /
• pp.89-103
• /
• 2007

• Proceedings of the Korean Society of Toxicology Conference
• /
• 2000.11a
• /
• pp.265-315
• /
• 2000

• Proceedings of the Korean Society of Toxicology Conference
• /
• 1998.10a
• /
• pp.55-55
• /
• 1998

• Proceedings of the PSK Conference
• /
• 2004.10a
• /
• pp.112-112
• /
• 2004

• Proceedings of the PSK Conference
• /
• 2004.10a
• /
• pp.113-114
• /
• 2004